Diabetes mellitus onset in geriatric patients: Does long-term atypical antipsychotic exposure increase risk?

Psychogeriatrics

Volumn 15, Issue 1, 2015, Pages 43-50

  Abitbol, Roza ^a   Rej, Soham ^b   Segal, Marilyn ^b   Looper, Karl J ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Antidepressants; Atypical antipsychotic; Depression; Diabetes mellitus; Hyperglycaemia; Valproate

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR; GLUCOSE; INSULIN; LITHIUM; MIRTAZAPINE; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; NEUROLEPTIC AGENT;

AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DRUG EXPOSURE; FEMALE; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INCIDENCE; LONG TERM CARE; LONG TERM EXPOSURE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; WEIGHT GAIN; AMBULATORY CARE; BLOOD; CASE CONTROL STUDY; CHEMICALLY INDUCED; CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; MENTAL DISORDERS; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84924735596     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/psyg.12081     Document Type: Article

References (31)

1. Boyle JP, Honeycutt AA, Narayan KM etal. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001; 24: 1936-1940.
2. Sclater AL. Diabetes in older persons: special considerations. West J Med 1998; 168: 532-533.
3. Meneilly GS, Tessier D. Diabetes in elderly adults. J Gerontol A Biol Sci Med Sci 2001; 56: M5-13.
4. Scheen AJ. Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion? Diabetes Metab 2005; 31 (Spec No 2): 5S27-5S34.
5. Bai YM, Su TP, Chen MH, Chen TJ, Chang WH. Risk of developing diabetes mellitus and hyperlipidemia among patients with bipolar disorder, major depressive disorder, and schizophrenia: a 10-year nationwide population-based prospective cohort study. J Affect Disord 2013; 150: 57-62.
6. Dinan TG. Schizophrenia and diabetes 2003: an expert consensus meeting. Introduction. Br J Psychiatry Suppl 2004; 47: S53-S54.
7. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005; 17: 83-93.
8. Ferentinos P, Dikeos D. Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics. Curr Opin Psychiatry 2012; 25: 381-390.
9. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012; 8: 114-126.
10. Henderson DC, Cagliero E, Copeland PM etal. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62: 19-28.
11. Manu P, Correll CU, Wampers M etal. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone. Schizophr Res 2013; 143: 358-362.
12. Bou Khalil R. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies. Clin Neuropharmacol 2012; 35: 141-147.
13. Okumura Y, Ito H, Kobayashi M, Mayahara K, Matsumoto Y, Hirakawa J. Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study. Schizophr Res 2010; 119: 145-152.
14. de Almeida KM, Moreira CL, Lafer B. Metabolic syndrome and bipolar disorder: what should psychiatrists know? CNS Neurosci Ther 2012; 18: 160-166.
15. Lipscombe LL, Levesque L, Gruneir A etal. Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch Intern Med 2009; 169: 1282-1289.
16. Lipscombe LL, Levesque LE, Gruneir A etal. Antipsychotic drugs and the risk of hyperglycemia in older adults without diabetes: a population-based observational study. Am J Geriatr Psychiatry 2011; 19: 1026-1033.
17. De Hert M, van Winkel R, Van Eyck D etal. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health 2006; 2: 14.
18. Saltz BL, Robinson DG, Woerner MG. Recognizing and managing antipsychotic drug treatment side effects in the elderly. Prim Care Companion J Clin Psychiatry 2004; 6 (Suppl 2): 14-19.
19. Feig DS, Palda VA, Lipscombe L, Canadian Task Force on Preventive Health C. Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2005; 172: 177-180.
20. Rej S, Herrmann N, Shulman K. The effects of lithium on renal function in older adults-a systematic review. J Geriatr Psychiatry Neurol 2012; 25: 51-61.
21. Watanabe N, Omori IM, Nakagawa A etal. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 2010; 24: 35-53.
22. Bet PM, Hugtenburg JG, Penninx BW, Hoogendijk WJ. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol 2013; 23: 1443-1451.
23. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161: 1709-1711.
24. Henderson DC, Cagliero E, Copeland PM etal. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry 2007; 68: 533-541.
25. Al-Zoairy R, Ress C, Tschoner A, Kaser S, Ebenbichler C. The effects of psychotropic drugs on the regulation of glucose metabolism. Curr Diabetes Rev 2013; 9: 362-370.
26. Mezuk B, Johnson-Lawrence V, Lee H etal. Is ignorance bliss? Depression, antidepressants, and the diagnosis of prediabetes and type 2 diabetes. Health Psychol 2013; 32: 254-263.
27. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000; 23: 934-942.
28. Verrotti A, D'Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev 2011; 12: e32-e43.
29. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379: 721-728.
30. Svendal G, Fasmer OB, Engeland A, Berk M, Lund A. Co-prescription of medication for bipolar disorder and diabetes mellitus: a nationwide population-based study with focus on gender differences. BMC Med 2012; 10: 148.
31. Bai YM, Lin CC, Chen JY, Chen TT, Su TP, Chou P. Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study. J Clin Psychiatry 2011; 72: 751-756.